Kyverna Therapeutics’ anti-CD19 CAR-T is drawing new investors to lead a $60 million infusion, reloading as it steers through early clinical trials in autoimmune diseases.
Bain Capital Life Sciences and GordonMD Global Investments led the Series B extension, which brought the round to $145 million.
Emeryville, CA-based Kyverna counts itself…
Click here to view original post
